Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Dig Dis Sci. 2010 Oct;55(10):2922-8. doi: 10.1007/s10620-009-1094-8. Epub 2010 Jan 20.
Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) appear to have increased intestinal permeability; it has been suggested that activation of protease-activated receptor-2 (PAR-2) receptors is responsible for this alteration. The aims of this study are to evaluate (1) if rectal (large bowel) permeability is increased in IBS-D and (2) if tryptase plays a critical role in the altered permeability.
Rectal biopsies from 20 patients with IBS-D and 30 subjects without the condition (normal controls) were assessed for macromolecular permeability using horseradish peroxidase in Ussing chambers in the basal state and after addition of drugs to the basolateral side. Reverse-transcription polymerase chain reaction (RT-PCR) was performed using colonic biopsy tissues from patients with IBS-D and normal subjects.
When tryptase was added to the basolateral (not mucosal) side of normal rectal biopsy tissues, permeability appeared to be proportional to the increase in tryptase concentration (P < 0.05) and was abolished by the addition of tryptase inhibitor (100 μM nafamostat; 1.568 ± 0.874 ng/2 h/mm(2) to 0.766 ± 0.661 ng/2 h/mm(2), n = 14, respectively, P < 0.01). Intestinal permeability in patients with IBS-D was significantly increased compared with controls (0.848 ± 0.0.600 ng/2 h/mm(2), n = 21, P < 0.01). Nafamostat significantly reduced the enhanced permeability in IBS-D (0.934 ± 0.589 ng/2 h/mm(2) to 0.247 ± 0.263 ng/2 h/mm(2), n = 14, respectively, P < 0.05). Transcription levels of PAR2 measured by RT-PCR did not differ between IBS-D and normal subjects.
Tryptase seems to play an important role in the control of human colonic mucosal permeability, and enhanced tryptase activity was responsible for the increased permeability of rectal mucosa in IBS patients.
腹泻型肠易激综合征(IBS-D)患者的肠道通透性似乎增加;有人提出,蛋白酶激活受体-2(PAR-2)受体的激活是这种改变的原因。本研究的目的是评估(1)IBS-D 患者的直肠(大肠)通透性是否增加,(2)胰蛋白酶是否在改变的通透性中起关键作用。
在基础状态下和向基底外侧添加药物后,使用辣根过氧化物酶在 Ussing 室中评估 20 例 IBS-D 患者和 30 例无该疾病(正常对照)患者的直肠活检组织的大分子通透性。使用 IBS-D 患者和正常受试者的结肠活检组织进行逆转录聚合酶链反应(RT-PCR)。
当胰蛋白酶被添加到正常直肠活检组织的基底外侧(非黏膜侧)时,通透性似乎与胰蛋白酶浓度的增加成正比(P < 0.05),并且添加胰蛋白酶抑制剂(100 μM 那法司特;1.568 ± 0.874 ng/2 h/mm2 至 0.766 ± 0.661 ng/2 h/mm2,n = 14,分别,P < 0.01)可使其消失。IBS-D 患者的肠道通透性明显高于对照组(0.848 ± 0.0.600 ng/2 h/mm2,n = 21,P < 0.01)。那法司特显著降低 IBS-D 中增强的通透性(0.934 ± 0.589 ng/2 h/mm2 至 0.247 ± 0.263 ng/2 h/mm2,n = 14,分别,P < 0.05)。通过 RT-PCR 测量的 PAR2 的转录水平在 IBS-D 与正常受试者之间没有差异。
胰蛋白酶似乎在控制人类结肠黏膜通透性方面起着重要作用,而增强的胰蛋白酶活性是导致 IBS 患者直肠黏膜通透性增加的原因。